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Abst rac t
Introduction: Single nucleotide polymorphisms (SNPs) of the HLA-C and ERAP1 genes were recently determined 
to contribute to psoriasis susceptibility. However, data regarding the association of these genes with specific sub-
groups of psoriasis are scarce.
Aim: To examine the possible association of the HLA-C and ERAP-1 polymorphisms with early and late onset pso-
riasis and psoriatic arthritis.
Material and methods: Five ERAP1 SNPs and two HLA-C SNPs were genotyped in 105 psoriatic arthritis patients, 
214 cutaneous psoriasis patients and 200 healthy individuals. Haplotypes were constructed for three ERAP1 SNPs 
(rs17482078, rs10050860, rs30187), and interaction between HLA-Cw*0602 and ERAP1 was also analysed.
Results: The HLA-Cw*0602 rs10484554 SNP was found to be a strong susceptibility factor for early onset cutaneous 
psoriasis and early onset psoriatic arthritis. ERAP1 SNPs (rs10050860, rs17482078, rs27525) appear to have a protec-
tive function for early onset psoriatic arthritis. The haplotype B was identified as a susceptibility factor for late onset 
psoriatic arthritis. In HLA-C positive individuals the rs27524 ERAP1 SNP was associated with a significantly increased 
risk of psoriatic arthritis development, whereas the rs27525 ERAP1 SNP had the opposite effect.
Conclusions: These results suggest that the HLA-C and ERAP1 genes contribute to the pathogenesis of psoriasis 
and psoriatic arthritis in an age-dependent manner.
Key words: HLA-C, ERAP1, psoriasis, psoriatic arthritis, polymorphism.
Introduction 
Psoriasis is a common, chronic immune-mediated 
skin disease. Clinically, psoriasis is characterized by the 
presence of well-demarcated, scaly, erythematous skin 
lesions, and is frequently associated with arthritis [1]. 
Psoriatic arthritis is a seronegative inflammatory arthritis 
present in nearly 25% of patients with psoriasis and de-
velops after an average interval of about one decade [2]. 
Psoriatic arthritis is defined as a subtype of spondyloar-
thropathies, based on common human leukocyte antigen 
(HLA) associations. Clinically, this disease is characterized 
by changing degrees of oligoarthritis, polyarthritis and 
spondylitis and typically involves dactylitis, distal inter-
phalangeal joint involvement or mutilating arthritis [2, 3]. 
Early onset psoriasis, or type I psoriasis, refers to pa-
tients with an onset before 40 years of age, more serious 
disease course than the late onset psoriasis, strong fam-
ily history, and HLA-C*06 positivity. Early onset psoria-
sis has been reported in 75% of patients with psoriasis; 
hence, it affects the majority of patients with psoriasis. 
Late onset psoriasis, or type II psoriasis, in contrast, is 
characterized by an onset at or after 40 years, less se-
vere clinical symptoms and rare family inheritance [4, 5]. 
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Recently, age at disease onset (with a cut-off value at 
40 years) has been found similarly important in the char-
acterization of the disease phenotype in psoriatic arthri-
tis as well [6].
Single nucleotide polymorphisms (SNPs) of several 
genes have been identified as contributing to psoriasis 
susceptibility [7, 8]. We and others have previously re-
ported a significant association with variants of the HLA-
Cw*0602, IL23R, LCE3C, LCE3B-del [9, 10], IL12R, IL23 [11], 
TNFSF15 [3], and ERAP1 genes [12–14]. Psoriatic arthritis 
is strongly associated with the HLA-B13, HLA-B57, HLA-
B39, HLA-Cw6 and HLA-Cw7 alleles [8]. While psoriatic 
arthritis tends to have a more severe disease course and 
appears earlier in HLA-B*27 positive patients, the latency 
between the onset of psoriasis and onset of joint symp-
toms is longer in HLA-Cw*0602 positive patients [6, 15].
Genetic variants of the endoplasmic reticulum-asso-
ciated amino-peptidase 1 (ERAP1) gene has recently been 
reported to be associated with ankylosing spondylitis 
(AS), psoriasis [16], and Behcet’s disease [17]. The ERAP1 
protein belongs to the M1 family of zinc metallopeptidase 
enzymes and is encoded by a gene on chromosome 5q15 
[18]. ERAP1 trims peptides imported into the endoplas-
mic reticulum at their N-terminus and contributes to the 
shaping of the antigenic repertoire presented by class I 
major histocompatibility complex (MHC) molecules [19]. 
Depending on the peptide length and sequence compo-
sition, ERAP1 has the ability to both destroy and create 
peptide cargos for MHC class I molecules [20]. The ERAP1 
protein also contributes to the shedding of the mem-
brane-bound receptors of inflammatory cytokines, such 
as IL-1R2, TNFR1 and IL-6R [21]. ERAP1 likely plays a pivot-
al role in the protection from infectious diseases by con-
tributing to the maintenance of immune tolerance and 
control of inflammation [22]. The association of ERAP1 
variants with psoriasis has been investigated recently 
in populations of European and Chinese ancestry. Two 
ERAP1 variants, rs27524 (noncoding) and rs30187 (Ly-
s528ARG), were found to be genome-wide risk factors for 
psoriasis [12]. Furthermore, dominant epistasis between 
HLA-Cw*0602 and the ERAP1 rs30187 SNP was identified 
in studies [12–14]. Another recent work identified the 
ERAP1 rs27432 SNP (intronic) as a variant strongly asso-
ciated with psoriasis [23]. In Han Chinese populations, 
ERAP1 SNPs or gene variants in linkage disequilibrium 
with ERAP1 SNPs were also found to be associated with 
psoriasis [24–26]. It is currently unclear whether the ef-
fects of ERAP1 on psoriasis can be explained by a single 
variant or by allotypic associations. Recently, the asso-
ciation of ERAP1 with psoriatic arthritis has also been 
investigated; however, this study did not demonstrate 
an association between rs30187 and psoriatic arthritis 
or psoriatic arthritis subphenotypes [27].
As psoriasis is currently best stratified by disease 
onset and absence or presence of arthritis, we hypoth-
esized that stratifying psoriasis patients into early and 
late onset groups, as well as skin-only and arthritis sub-
groups leads to the identification of new ERAP1 geno-
type–phenotype associations. Furthermore, as ERAP1 
seems to be associated with inflammatory diseases in 
a HLA-dependent manner, we also intended to explore 
whether a gene–gene interaction between HLA-Cw*0602 
and ERAP1 exists in these well-stratified subgroups of 
psoriatic patients. 
Aim
Furthermore, as ERAP1 seems to be associated with 
inflammatory diseases in a HLA-dependent manner, we 
also intended to explore whether a gene–gene interac-
tion between HLA-Cw*0602 and ERAP1 exists in these 
well-stratified subgroups of psoriatic patients. We have 
analysed the association of five ERAP1 and two HLA-
Cw*0602 SNPs as well as different ERAP1 haplotypes with 
EOP, LOP and psoriatic arthritis.
Material and methods
Subjects
This study was approved by the Internal Review 
Board of the University of Szeged, the approval number is 
PSO-GENET-001. Informed consent was obtained from all 
participating patients and volunteers, and the study was 
conducted in full accordance with the principles of the 
Declaration of Helsinki. The study population consisted 
of 319 Hungarian Caucasian psoriasis vulgaris patients 
(designated as PsV) treated at the Department of Derma-
tology and Allergology and the Department of Rheuma-
tology of the University of Szeged, and at the Department 
of Rheumatology of Pándy Kálmán Békés County Hos-
pital, Gyula, as well as 200 ethnically-matched healthy 
individuals with no known multifactorial inflammatory 
diseases. Of the 319 psoriasis vulgaris patients, 105 ex-
hibited psoriatic arthritis (designated as PsA), fulfilling 
the Classification Criteria for Psoriatic Arthritis (CASPAR). 
The group of patients with psoriatic arthritis was further 
stratified into five homogenous clinical groups according 
to the Moll and Wright criteria [28]. Patients with skin 
symptoms of psoriasis only were denoted as cutaneous 
psoriasis (designated as PsC) patients. Patients with on-
set before 40 years of age were classified as having early 
onset psoriasis (EO-PsV, EO-PsA, EO-PsC), whereas late 
onset psoriasis (LO-PsV, LO-PsA, LO-PsC) was defined by 
an onset at or after 40 years. The demographic and clini-
cal characteristics of the study population are listed in 
Table 1. 
Genotyping and haplotype analysis
Genomic DNA was isolated from venous blood of pa-
tients and controls using the BioRobot EZ and the EZ1 
DNA Blood Kit from QIAGEN (Hilden, Germany), accord-
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ing to the instructions of the manufacturer. Genotyping 
of five SNPs of the ERAP1 gene and two SNPs of the HLA-
Cw*0602 gene (Table 2), previously reported as candidate 
genes and SNPs in the pathogenesis of psoriasis and AS 
[16, 29], was carried out with the PCR-based Assay-by-
Design method of Applied Biosystems (Foster City, CA), 
following the instructions of the manufacturer. After PCR 
amplification, end-point detection was performed with 
a CFX 96 real-time PCR machine from Bio-Rad (Hercules, 
CA). Genotyping of the rs10484554 SNP was used to de-
termine the HLA-C status, as previously reported [12, 16]. 
Three SNPs (rs30187, rs10050860, rs17482078) were used 
to construct four haplotypes: Haplotype A (rs17482078/
rs10050860/rs30187-CCC), Haplotype B (rs17482078/
rs10050860/rs30187-CCT), Haplotype C (rs17482078/
rs10050860/rs30187-TTC) and Haplotype D (rs17482078/
rs10050860/rs30187-TTC, previously reported by Ombrel-
lo et al. to be risk or protective factors in AS [30].
Statistical analysis
Genotype frequencies, frequencies of the main haplo-
types and SNP associations were calculated and compared 
between patient groups using Fisher’s exact test, using the 
Plink software package (v1.9). Odds ratios were calculated 
with 95% confidence intervals. Multiple-testing correction 
was applied to all comparisons using the Benjamini-Hoch-
berg ‘FDR’ method in R (v3.2.3), with a significance thresh-
old of p < 0.05. As previously suggested and successfully 
applied by other authors [31–33], the age of 40 years was 
used for stratification of age at disease onset. No further 
stratification of age at disease onset was attempted due 
to the relatively small number of patients.
Results
The genotype frequencies of the HLA-C and ERAP1 
SNPs are summarized in Table 3. Genotype frequencies 
in patients and controls were in Hardy-Weinberg equi-
librium. Control genotype frequencies were comparable 
to those published in the literature. The genotype distri-
bution of one HLA-C SNP (rs10484554) was found to be 
significantly different between the PsV patients and the 
group of healthy individuals (p = 5.9 × 10–5 respectively). 
The proportion carrying the mutant HLA-Cw*0602 allele 
(rs10484554 SNP) was significantly higher among PsV pa-
tients than in the group of healthy controls (58.3% and 
36.5%, respectively), and there was no difference in this 
respect between patients with skin only or skin and joint 
symptoms (57.9% and 59%, respectively). Taken together, 
the HLA-Cw*0602 rs10484554 SNP seems to be a strong 
susceptibility factor for psoriasis (Table 3). In the case 
of the five other ERAP1 SNPs (rs27524, rs27525, rs30187, 
rs17482078 and rs10050860) and rs10484545 HLA-C SNP, 
there were no statistically detectable differences in the 
genotype distributions between healthy individuals and 
the PsV patients. 
Table 2. ERAP1 and HLA-Cw*0602 gene SNPs
Chr. Gene SNP Kit number Nucleotide change Variation
5 ERAP1 rs27524 C___3056837_10 A/G None
5 ERAP1 rs27525 C___3056838_10 C/T None
5 ERAP1 rs30187 C___3056885_10 C/T Lys528ARG
5 ERAP1 rs17482078 C___3056871_10 C/T Arg725Gln
5 ERAP1 rs10050860 C___3056876_10 C/T Asp575Asn
6 HLA-C rs10484545 C___29666895_10 C/G None
6 HLA-C rs10484554 C___29612773_20 C/T None









Age, mean (range) [years] 40.39 ±19 (7–82) 52.13 ±21 (17–82) 50.72 ±19 (17–81) 54.34 ±13 (27–82)
Males/females [N, (%)] 77 (39)/123 (41) 177 (55)/142 (45) 125 (58)/89 (42) 52 (49)/53 (51)
PASI, mean (range) – – 12.42 ±16.54 (0.1–52.8) –
Arthritis, distal [N, (%)] – – – 13 (12)
Asymmetrical oligoarthritis [N, (%)] – – – 28 (27)
Symmetrical polyarthritis [N, (%)] – – – 45 (43)
Arthritis, axial [N, (%)] – – – 19 (18)
Arthritis mutilans [N, (%)] – – – 0 (0)
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Subsequently, psoriasis vulgaris patients were sub-
divided into groups according to the presence or ab-
sence of arthritis (Table 3). In line with earlier publica-
tions [29, 32, 34], the genotype distribution of the HLA-C 
rs10484554 SNP was found to be significantly different 
in both the PsC and the PsA subpopulations (p = 0.0007 
and p = 0.0007, respectively), compared to healthy con-
trols. In PsA (but not in PsC) patients, the genotype dis-
tribution of three ERAP1 SNPs (rs10050860, rs27525 and 
rs17482078) was also significantly different (p = 0.0252, 
p = 0.0453 and p = 0.0453, respectively) (Table 3). For 
all three SNPs, the proportion of patients carrying the 
wild type allele was higher than in the group of healthy 
individuals, suggesting that the rare allele of these SNPs 
might provide protection against the development of 
psoriatic arthritis. As no differences were detected in 
the genotype distribution of the studied ERAP1 SNPs in 
PsC patients, it is likely that the trend in the difference 
observed for the rs10050860 SNP in the PsV patients is 
caused by the presence of the PsA patients. No difference 
was detected for the ERAP1 rs27524 and rs30187 SNPs 
and the HLA-C rs10484545 SNP between the healthy con-
trols and the psoriasis groups, even after stratification 
for arthritis.
We further stratified patients according to disease 
onset (early and late onset). Significant differences were 
observed only for the HLA-C rs10484554 SNP in the early 
onset groups, which is in agreement with earlier publi-
cations [13, 14, 29, 34]. This result suggests that HLA-C 
positivity is a susceptibility factor only for early onset 
psoriasis. Stratification led to no significant difference for 
the rs10484545 HLA-C SNP. The ERAP1 SNPs (rs10050860, 
rs27525 and rs17482078) known to be associated with 
psoriatic arthritis were found to have only a tendency in 
the association with EO-PsA patients (p = 0.0663, p = 
0.0663 and p = 0.0997, respectively) (Table 3). This lends 
further support to the notion that the differences in dis-
tribution of these SNPs detected in the total PsA group 
are primarily driven by the early onset subpopulation, 
and that these ERAP1 SNPs presumably provide protec-
tion against early onset psoriatic arthritis. 
The ERAP1 rs17482078, rs10050860, rs30187 and 
rs2287987 SNPs were found to be in strong linkage dis-
equilibrium, and the association between haplotypes 
including these SNPs and AS was recently reported 
[35]. A linkage disequilibrium block containing the 
rs17482078/rs10050860/rs30187 SNPs was also identi-
fied in our dataset (Figure 1). Thus, we examined whether 
the rs17482078/rs10050860/rs30187 haplotypes were as-
sociated with psoriasis susceptibility (Table 4). We found 
that Haplotype B (rs17482078/rs10050860/rs30187-CCT) 
was a risk factor only for LO-PsV (p = 0.0409) and for 
LO-PsA (p = 0.0413).
As it was reported earlier that some ERAP1 variants 
influence psoriasis susceptibility exclusively in individu-
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ERAP1 SNPs in HLA-C positive psoriasis and psoriatic ar-
thritis patients. ERAP1 SNP frequencies were compared 
between individuals carrying at least one copy of the 
risk allele of rs10484554 (HLA-C positive) and individu-
als not carrying the HLA-C sequence (HLA-C negative) 
(Table 5). Evidence for association in HLA-C positive in-
dividuals was observed for two loci. The ERAP1 rs27524 
SNP in HLA-C positive individuals exhibited a 1.74-fold 
increased risk of PsV (p = 0.0454) and a 2.33-fold risk of 
PsA (p = 0.0185), in agreement with the previous report 
[12]. Interestingly, rs27524 by itself was not associated 
in our dataset with either PsV or PsC and was found to 
have a tendency as a susceptibility factor only for LO-PsA 
(Table 3). The ERAP1 rs27525 SNP decreased the risk of 
psoriatic arthritis development in HLA-C positive patients 
(odds ratio (OR) 0.42, p = 0.0339). Thus, the presence of 
the ERAP1 rs27525 SNP seems to protect HLA-C positive 
individuals from developing psoriatic arthritis. No other 
interaction was found for the ERAP1 rs30187, rs10050860 
and rs17482078 SNPs in HLA-C positive individuals, even 
after further stratifying the patients into early and late 
onset subgroups. 
Discussion
Psoriasis has been associated with the PSORS1 
disease susceptibility locus of the MHC class I region 
on chromosome 6. Within PSORS1, the HLA-Cw6 gene 
has shown the strongest association with psoriasis [8]: 
about 60% of psoriasis patients carry the HLA-Cw*0602 
allele. HLA-C positive patients exhibit earlier disease 
onset, higher incidence of guttate and eruptive type of 
psoriasis, more extensive disease symptoms, and more 
frequent exacerbations caused by throat infections 
than HLA-C negative individuals. The frequency of HLA-
Cw*0602 is significantly lower in patients with psoriatic 
arthritis compared with those with psoriasis alone, and 
its presence is associated with a longer psoriasis–arthri-
tis interval and milder arthritis forms [34, 36, 37].
In this study, a well-characterized cohort of psoriasis 
patients was available for investigating whether HLA-
Cw6 or ERAP1 gene polymorphisms are associated with 
different clinical phenotypes of psoriasis and psoriatic 
arthritis. Our dataset included patients with early and 
late onset psoriasis vulgaris, as well as with cutaneous 
psoriasis and psoriatic arthritis. 
Our results confirmed the previously reported genetic 
association of psoriasis with both HLA-Cw6 and ERAP1 
genes [12–14]. The HLA-Cw*0602 rs10484554 SNP was 
found to have a very strong association with PsV, and the 
association was highly significant with both PsC and PsA 
groups as well (although somewhat stronger with PsC). 
Interestingly, only EO-PsV was associated with HLA-C 
in our dataset. Previously, the HLA-Cw*06 allele was 
not found to be a risk factor for late onset psoriasis in 
a Northern Polish population [38], and late onset pso-
riasis demonstrated only a weak association with HLA-
Cw*06 alleles in other studies [13, 39]. More recently, 
however, a study using dense genotyping revealed that 
HLA-Cw*06 is associated with late onset psoriasis [40].
























































































Total (N = 319) 58 (18.2) 0.8153 Total (N = 214) 35 (16.4) 0.4804 Total (N = 105) 23 (21.9) 0.5468
Early (N = 195) 36 (18.5) 0.8909 Early (N = 132) 18 (13.6) 0.2015 Early (N = 63) 18 (28.6) 0.1056
Late (N = 124) 22 (17.7) 0.7769 Late (N = 82) 17 (20.7) 0.7389 Late (N = 42) 5 (11.9) 0.2741




Total (N = 319) 148 (46.4) 0.1531 Total (N = 214) 97 (45.3) 0.2736 Total (N = 105) 51 (48.6) 0.1508
Early (N = 195) 84 (43) 0.5349 Early (N = 132) 57 (43.2) 0.5644 Early (N = 63) 27 (42.9) 0.6873
Late (N = 124) 64 (51.6) 0.0409 Late (N = 82) 40 (48.8) 0.1756 Late (N = 42) 24 (57.1) 0.0413




5) Total (N = 319) 64(20) 0.5220 Total (N = 214) 45 (21) 0.7184 Total (N = 105) 19 (18.1) 0.4624
Early (N = 195) 43(22.1) 0.8875 Early (N = 132) 32 (24.2) 1 Early (N = 63) 11 (17.6) 0.5169
Late (N = 124) 21 (16.9) 0.3125 Late (N = 82) 13 (15.9) 0.3149 Late (N = 42) 8 (19) 0.7642




5) Total (N = 319) 44 (13.8) 0.3985 Total (N = 214) 34 (15.9) 0.8658 Total (N = 105) 10 (9.5) 0.0962
Early (N = 195) 28 (14.4) 0.5560 Early (N = 132) 22 (16.7) 0.9681 Early (N = 63) 6 (9.5) 0.1742
Late (N = 124) 16 (12.9) 0.3798 Late (N = 82) 12 (14.6) 0.6976 Late (N = 42) 4 (9.5) 0.1842
Frequency is listed as [N, (%)]. * Significant compared to healthy controls carrying the given haplotype.
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Genetic variants of ERAP1 have recently been re-
ported to be associated with psoriasis [13, 14, 16]. ERAP1 
trims peptides imported into the endoplasmic reticulum 
at their N-terminus and contributes to the shaping of the 
antigenic repertoire presented by class I MHC molecules 
[19]. The association of ERAP1 with psoriatic arthritis has 
previously been investigated; however, no association 
between ERAP1 SNPs and psoriatic arthritis or psoriatic 
arthritis subphenotypes was identified [27]. Recently, 
ERAP1 association with psoriasis was detected in pa-
tients with an age of onset between 10 and 20 years, and 
no association was detected in cases with onset below 
10 years [16]. 
Our results suggest that the HLA-C rs10484554 SNP 
contributes to psoriasis susceptibility. The proportions 
of the rare alleles of the ERAP1 rs27525, rs17482078 and 
rs10050860 SNPs were higher in the group of healthy 
individuals, suggesting that individuals with the rare al-
leles of these SNPs might be protected against psoriasis. 
These associations were also apparent when groups of 
psoriatic patients were analysed separately according to 
the presence or absence of arthritis. The stratification of 
the patients for early (< 40 years) or late (≥ 40 years) dis-
ease onset revealed an age-dependent difference in the 
genetic background of psoriasis: the associations with 
these SNPs tend to be stronger in patients with early 
disease onset. 
Although ERAP1 was neither dependent on nor inter-
acting with HLA-C*06:02 in certain populations, an inter-
action between HLA-C and ERAP1 was reported recently 
and confirmed several times subsequently [9, 12–14]. 
Interestingly, dominant epistasis between HLA-Cw*0602 
and one of the ERAP1 SNPs was identified recently in 
psoriasis [23]. 
Recent studies of the ERAP1 rs27524 SNP reported as-
sociation with the pathogenesis of psoriasis, especially 
in the group with age of disease onset between 10 and 
20 years [16, 41]. Our results revealed only a trend in as-
sociation with the late disease onset group, for which it 
might increase the likelihood of psoriasis development. 
No association with psoriasis was observed for the ERAP1 
rs30187 SNP in this study, which is in contrast with previ-
ous studies [12, 16]; however, Jadon et al. also reported 
that there was no association with psoriatic arthritis [27]. 
In addition, this psoriasis-risk allele, which is common in 
the European population, was not associated with the 
disease in an East Asian population [24]. 
Psoriatic arthritis patients, especially in the early on-
set group, carrying the ERAP1 rs27525 and rs17482078 
SNPs seem to be protected from the subsequent devel-
opment of the disease. Individuals carrying the rare al-
lele of the ERAP1 rs10050860 SNPs might be protected 
against psoriasis, but this effect was more prominent 
among patients with psoriatic arthritis, especially in the 
early onset group. These findings suggest that these 
three SNPs (rs27525, rs17482078, rs10050860) might be 
protective against psoriatic arthritis. 
The two coding ERAP1  SNPs (rs17482078 and 
rs10050860) and the rs30187 SNP are in linkage dis-
equilibrium (Figure 1) and have been reported as a pro-






P PsV (N = 319) PsC (N = 214) PsA (N = 105)




7 Total (N = 319) 0.0506 1.72 0.99–2.97 Total (N = 214) 0.0869 1.66 0.93–2.98 Total (N = 105) 0.0818 1.84 0.92–3.67
Early (N = 195) 0.0643 1.73 0.97–3.09 Early (N = 132) 0.0837 1.74 0.93–3.28 Early (N = 63) 0.1812 1.70 0.78–3.69





0 Total (N = 319) 0.2402 0.72 0.41–1.25 Total (N = 214) 0.3092 0.73 0.40–1.33 Total (N = 105) 0.2893 0.68 0.34–1.39
Early (N = 195) 0.2550 0.71 0.39–1.28 Early (N = 132) 0.4206 0.77 0.40–1.46 Early (N = 63) 0.2090 0.59 0.26–1.34





78 Total (N = 319) 0.2080 0.70 0.40–1.22 Total (N = 214) 0.2568 0.71 0.39–1.29 Total (N = 105) 0.2893 0.68 0.34–1.39
Early (N = 195) 0.2550 0.71 0.39–1.28 Early (N = 132) 0.3374 0.73 0.38–1.39 Early (N = 63) 0.3209 0.67 0.30–1.49




4 Total (N = 319) 0.0454 1.74 1.01–3.01 Total (N = 214) 0.1572 1.52 0.85–2.72 Total (N = 105) 0.0185 2.33 1.15–4.72
Early (N = 195) 0.0592 1.75 0.98–3.13 Early (N = 132) 0.1587 1.57 0.84–2.95 Early (N = 63) 0.0500 2.21 0.99–4.94




5 Total (N = 319) 0.1502 0.64 0.35–1.18 Total (N = 214) 0.3682 0.74 0.38–1.43 Total (N = 105) 0.0516 0.48 0.23–1.01
Early (N = 195) 0.1142 0.60 0.31–1.14 Early (N = 132) 0.3473 0.72 0.36–1.44 Early (N = 63) 0.0339 0.42 0.19–0.94
Late (N = 124) 0.4530 0.75 0.35–1.61 Late (N = 82) 0.6254 0.80 0.33–1.94 Late (N = 42) 0.4278 0.65 0.23–1.87
*Individuals carrying at least one copy of the rare allele of the rs10484554 HLA-C SNP and both wild type alleles of the indicated ERAP1 SNP (HLA-C positive/
ERAP1 negative) are compared with individuals carrying at least one copy of the rare allele of the rs10484554 HLA-C SNP and at least one copy of the rare allele 
of the indicated ERAP1 SNP (HLA-C positive/ERAP1 positive).
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tective haplotype (rs17482078/rs100508607rs30187/
rs2287987–TTCC) in HLA-B positive AS patients [35]. Also 
the rs17482078/rs10050860/rs30187-CCT haplotype was 
confirmed as a risk factor for AS [42] in an AS popula-
tion in Belgium, which we examined as Haplotype B 
(rs17482078/rs10050860/rs30187-CCT) in psoriasis sus-
ceptibility similarly to AS [35], and it was found to be 
a risk factor for only LO-PsV (p = 0.0409) and LO-PsA 
(p = 0.0413). We were unable to find any association 
with psoriasis or with psoriatic arthritis for Haplotype A 
(rs17482078/rs10050860/rs30187-CCC), Haplotype C 
(rs17482078/rs10050860/rs30187-TTC) and Haplotype D 
(rs17482078/rs10050860/rs30187-TTC). These data sug-
gest that the Haplotype B conferring disease risk in AS 
also influences susceptibility to joint involvement in pso-
riasis. 
Genome-wide association studies identified the in-
teraction between the ERAP1 rs27524 SNP and the HLA-C 
rs10484554 SNP; this interaction was the most promi-
nent among individuals carrying one or two copies of the 
risk allele at rs10484554 [12]. In subsequent analysis, the 
association with ERAP1 was not restricted to individuals 
carrying HLA-Cw*0602; however the genetic association 
with ERAP1 (rs207524, rs30187, rs26653) in psoriasis was 
confined to individuals with an age of disease onset be-
tween 10 and 20 years [16]. In a Polish population, ERAP1 
rs27524 SNP was a susceptibility factor for HLA-C positive 
patients with late onset psoriasis [13]. In our study, the 
ERAP1 rs27524 SNP in HLA-C positive individuals caused 
a 1.74-fold increased risk of PsV (p = 0.0454) and a 2.33-
fold risk of PsA (p = 0.0185). Notably, the rs27524 SNP 
by itself was not associated either with PsV or with PsC 
in this dataset and was found to have only a tendency 
as a susceptibility factor for LO-PsA (Table 3). The ERAP1 
rs27525 SNP in HLA-C positive patients decreased the 
risk of psoriatic arthritis development (OR = 0.42, p = 
0.0339); thus, the presence of these SNPs seems to pro-
tect against developing psoriatic arthritis.
Taken together, our results suggest that the genetic 
variants of the ERAP1 and HLA-C genes contribute to the 
pathogenesis of psoriasis in a manner that is dependent 
on age of onset. Individuals with HLA-Cw*0602 are more 
prone to early onset of disease (before 40 years), con-
firming that onset after 40 years represents a biologically 
valid approximation for a genetically distinct subgroup 
of psoriasis. The overall psoriasis group was stratified by 
various clinical aspects, including the age of onset and 
the presence or absence of psoriatic arthritis. This novel 
and careful stratification of patients according to the 
symptoms and age of onset leads to important insights 
for psoriasis, a heterogeneous, multifactorial disease, 
and might become more important for further research 
as well as for personalized medicine. 
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